Quote | Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX)
Last: | $0.5799 |
---|---|
Change Percent: | 0.55% |
Open: | $0.5765 |
Close: | $0.5799 |
High: | $0.5799 |
Low: | $0.575 |
Volume: | 14,589 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX)
Clinical site to be Opened in Saudi Arabia Site Currently Treating Netherton Patients Who Are Eligible for Recruitment into Quoin Studies Experienced Local Clinical Research Organization Has Been Engaged Plans for the Opening of Additional International Sites at an Advan...
ASHBURN, Va., June 25, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announces that it will be a Bronze Sponsor for the Foundat...
Message Board Posts | Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX)
Subject | By | Source | When |
---|---|---|---|
Price gaining last trade up | 1968cuda434 | investorshub | 04/30/2023 9:56:08 AM |
$QNRX The now last up | TIMGZ | investorshub | 04/28/2023 9:44:52 PM |
Price now | crudeoil24 | investorshub | 04/27/2023 5:19:19 PM |
$QNRX Thoughts on where this is headed? | reena969 | investorshub | 04/26/2023 4:30:15 PM |
Do we have a winner?Turn around time? | Tadaia | investorshub | 04/26/2023 8:54:32 AM |
News, Short Squeeze, Breakout and More Instantly...
Quoin Pharmaceuticals Ltd. Company Name:
QNRX Stock Symbol:
NASDAQ Market:
Quoin Pharmaceuticals Ltd. Website:
Clinical site to be Opened in Saudi Arabia Site Currently Treating Netherton Patients Who Are Eligible for Recruitment into Quoin Studies Experienced Local Clinical Research Organization Has Been Engaged Plans for the Opening of Additional International Sites at an Advan...
ASHBURN, Va., June 25, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announces that it will be a Bronze Sponsor for the Foundat...
Agreement will focus on the development of novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare and orphan diseases UCC’s proprietary dissolvable microneedles technology and other approaches will be utilized to optimize the local delivery ...